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The great potential of mass spectrometry (MS)-based proteomics as a quantitative appli-
cation in clinical chemistry has been explored and shown since more than a decade. As a
result of maturation of strategies as well as MS-equipment, the ﬁeld of quantitative pro-
teomics now experiences a growing interest for implementation in the clinic. MS methods
have the potential to outperform the currently applied clinical immunoassays and offer
multiple opportunities to support standardization initiatives for the measurement of pro-
tein biomarkers in routine clinical practice. For successful introduction and broad use of
MS-based quantitative protein assays in clinical chemistry, several important concepts for
quality assurance generally accepted in the clinical chemistry community have to be borne
in mind.
To translate the quality speciﬁcations of routine clinical assays to newly developed
MS-based methods, common knowledge of the underlying principles to deﬁne minimal,
desirable and optimal analytical performance, such as those based on biological variation,
is essential. In this review critical steps in the complete quantitative clinical chemistry pro-
teomics (qCCP) workﬂow that may contribute to the total variation of the MS-procedure
are outlined, in particular for applications that involve liquid chromatography in com-bination with stable-isotope dilution methodology and multiple reaction monitoring MS
(LC–SID-MRM-MS).
Furthermore, in this review well-known clinical chemistry concepts of metrological trace-
ability and commutability of referencematerials are introducedwith regard toMS strategies,
and the potential of qCCP in standardization of clinical protein assays is emphasized.
Critical steps for safeguarding analytical performance at the pre-, and analytical phase,
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which include specimen collection, specimen stability, sample preparation, and LC–MS/MS
analysis, are discussed in detail. In addition, post-analytical constraints, such as traceable
reference intervals and decision limits, are considered.
he A
formance, (2) metrological traceability and commutability
of reference materials (RM) during development, and (3)© 2013 T
1. Introduction
Clinical immunoassays suffer from limitations and for numer-
ous analytes standardization efforts have not been successful
[1,2]. These aspects of immunoassays along with the recent
growth and development of mass spectrometry (MS)-based
quantitative proteomicsmakeMS-based protein assays highly
interesting for the clinical chemistry ﬁeld [1–4]. Prerequisites
for clinical applicability of protein biomarkers asmedical tests
are (1) the fulﬁlment of a well-deﬁned clinical need, and (2)
successful test evaluations [5]. To further anchor the clinical
utility of protein biomarkers, it is of paramount importance
that test results are traceable to standards of higher order,
when available, and have limited and deﬁned uncertainty [6].
The urgent need for standardization/harmonization is fur-
thermore prompted by the globalization of health care, which
necessitates accurate and metrologically traceable reference
intervals and decision limits; the obtained test results being
independent of method, location and time of analysis [7].
In the ﬁeld of quantitative proteomics, stable-isotope dilu-
tion methodology (i.e. using reference standards that are
labelled with stable, naturally occurring isotopes) in combi-
nation with multiple reaction monitoring mass spectrometry
(SID-MRM-MS) after enzymatic cleavage of the target protein
is rapidly emerging, and themost commonly applied approach
for MS-based protein quantitation [3,8–11]. This approach
for protein quantitation (or identiﬁcation) via corresponding
proteolytic peptides is commonly referred to as bottom-up
or peptide-centric analysis [12,13]. In the case of SID-MRM-
MS, enzymatic (typically tryptic) digestion of complex protein
mixtures to yield peptide mixtures is followed by MRM-MS
analysis, and subsequent quantitation of the peptides of inter-
est (i.e. target or signature peptides) relative to stable-isotope
labelled standard (SIS-) peptides [14,15]. The seven critical ele-
ments during development of an MS-based protein assay have
recently been outlined in detail [16,17] and include proper
design of (1) internal standardization, (2) protein puriﬁcation,
(3) enzymatic digestion, (4) selection of the most appropriate
signature peptides, (5) peptide puriﬁcation, (6) liquid chro-
matography (LC) separation, and (7) MS-detection. Recently,
Lehmann and co-workers discussed several considerations
to further develop MS-based proteomics into a routine clin-
ical chemistry assay for protein quantitation [18]. In line with
these recommendations and requirements, we reiterate that
for the implementation of quantitative clinical chemistry pro-
teomics (qCCP), the seven critical factors should be extended
by pre- and post-analytical constraints to ensure the highest
diagnostic value of the measurement result [4]. The criti-
cal steps during the entire qCCP workﬂow are illustrated
in Fig. 1. Pre-analytical considerations include, among oth-
ers, specimen collection, transportation and sample handling,
whereas post-analytical processes include the clariﬁcation of
test purpose, test role, clinical performance as well as theuthors. Published by Elsevier B.V.
establishment of traceable reference intervals and/or decision
limits [5].
To ensure reliable and reproducible test results, the contri-
bution of all critical steps in the qCCP workﬂow to meet the
pre-deﬁned analytical performance criteria should be consid-
ered (Fig. 1). Theanalytical performanceof in-housedeveloped
MSmethods shouldnot exceed the total allowable error,which
in clinical chemistry is commonly derived from the biological
variation of the target protein within, and between, patients
[19]. Test evaluations should, therefore, consider whether
sufﬁcient analytical sensitivity and accuracy is obtained to
meet these pre-deﬁned quality speciﬁcations. In this respect,
multiple guidelines for validation of MS-based methods for
small molecules are available [20–27]. However, the special
requirements for validation of the critical steps in LC–MS/MS
measurement of protein biomarkers, e.g., the choice of target
peptides, the enzymatic digestion efﬁciency, or the calibration
strategy, have so farnot, or onlypoorly, beenaddressed [28–31].
Apart from method development and validation, continu-
ous monitoring of method performance and in-depth method
evaluation during routine clinical use are required. Internal
and external quality control procedures, therefore, deserve
speciﬁc attention during development and implementation
of qCCP methods. Useful guidelines are provided by the
Clinical and Laboratory Standards Institute (CLSI) [32–34]. In
addition, the increasing awareness of the need for quality
control of chromatographic separation, MRM speciﬁcity, and
data-analysis of quantitative proteomics workﬂows is demon-
strated by several recent publications [29,30].
To fulﬁl predeﬁned quality standards for analytical perfor-
mance of qCCP assays, essential clinical chemistry concepts
that support the standardization of clinical protein assays
should be acknowledged in the early-phase of method devel-
opment. These concepts include the metrological traceability
of test results, and the availability of commutable reference
materials.
In the present manuscript, basic clinical chemistry con-
cepts that are critical for analytical performance, quality
control, and standardization of test results are highlighted to
be taken into consideration during the introduction of LC–MS
methods for absolute protein quantitation in clinical chem-
istry.
2. Clinical chemistry concepts
Relevant clinical chemistry principles are covered in this
section to emphasize the importance of (1) analytical per-
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Fig. 1 – The analytical workﬂow of a qCCP assay from pre- to post-analysis. The analytical performance is deﬁned by the
total error, which depends on the accuracy (quality) of all steps in the workﬂow. The red texts indicate critical
factors/variables that can affect the total error (manual and/or instrumental variation not included). Boxes indicate
different processes within the workﬂow and circles© addition of patient or (internal) standard samples. Dashed lines
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.1. Analytical performance requirements
trategies that deﬁne and rationalize the analytical quality of
n vitro diagnostic tests in clinical chemistry are documented
n a hierarchy of objectivity in the Stockholm conference con-
ensus (Fig. 2) [35]. The highest level, which is based on clinical
utcome, is rarely available. Hence, quality speciﬁcations for
nalytical variation (CVa), bias (B), and total allowable error
1. Clinical Outcome 
2a. Clinicians Opinion 
2b. Biological Variation 
3. Professional 
4. External Quality Assessment / 
Proficiency Testing 
5. State of the Art 
ig. 2 – Stockholm consensus [35] hierarchy of approaches
o deﬁne quality requirements in clinical chemistry.ded at different points in the workﬂow.
(TEa) are generally based on the second level of the hierarchy,
i.e. the biological variability of the measurand [21,36,37].
Biological variation reﬂects the contribution of variations
within each patient (intra-individual variation or CVw), and
between patients (inter-individual variation or CVg) [36] to
the ﬁnal measurement result. Biological variation can be used
to deduce minimal, desirable or optimal values for bias, CVa
and TEa [19,36]. To assure that changes in test results reﬂect
the disease state, the combined contribution of imprecision
and non-speciﬁcity or calibration bias should, therefore, not
exceed the TEa derived from biological variation. For example,
the desirable CVa of a medical test is deﬁned as less than half
of the biological CVw [19].
Thus, for (protein) biomarkers with narrow distribution of
the CVw and CVg, analytical performance requirements for
bias and imprecision are more stringent. Examples of mini-
mal, desirable and optimal performance quality speciﬁcations
for bias, imprecision and TEa of several established clinical
protein biomarkers are shown in Table 1.
2.2. Metrological traceabilityTraceability is deﬁned as “the property of a measurement
result, or the value of a standard whereby it can be related to
stated references, usually national or international standards,
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Table 1 – Speciﬁcations for imprecision (I, CVa), bias (B) and total allowable error (TEa) based on within subject (CVw) and
between subject biological variation (CVg).
Protein Biological variation Minimal speciﬁcation Desirable speciﬁcation Optimal speciﬁcation
Uniprot nr CVw CVg I (%) B (%) TE (%) I (%) B (%) TE (%) I (%) B (%) TE (%)
Albumin P02768 3.1 4.2 2.4 2.0 5.9 1.6 1.3 3.9 0.8 0.7 2.0
Apolipoprotein A-I P02647 6.5 13.4 5.0 5.6 13.7 3.3 3.7 9.1 1.7 1.9 4.6
Apolipoprotein B P04114 6.9 22.8 5.3 9.0 17.4 3.5 6.0 11.6 1.8 3.0 5.8
CA 125 antigen Q8WX17 24.7 54.6 18.6 22.5 53.1 12.4 15.0 35.4 6.2 7.5 17.7
-Fetoprotein P02771 12.2 45.6 9.2 17.7 32.9 6.1 11.8 21.9 3.1 5.9 11.0
36.0
32.9IGF-1 P05019 14.6 45.4 11.0 17.9
Thyroglobulin P01266 14.0 39.0 10.5 15.6
through an unbroken chain of comparisons all having stated
uncertainties” [38]. An example of a complete traceability
chain with metrological traceability to SI Units (Système
International) is presented in Fig. 3.
The added value of the traceability of lab results to stan-
dards of higher order is broadly recognized by legislators since
Fig. 3 – General reference measurement system to achieve
metrological traceability to SI units. Abbreviations: CGPM,
general conference on weights and measures; NMI,
national metrology institute; ISO, International Scientiﬁc
Organisation; ARML, accredited reference measurement
laboratory; ML, manufacturer’s laboratory; ARCL, accredited
reference calibration laboratory; MCL, manufacturer’s
calibration laboratory.
The ﬁgure has been copied from (NEN-EN)-ISO 17511, 2003
and used with permission from NEN, Delft, the Netherlands
– www.nen.nl.7.3 11.9 24.0 3.7 6.0 12.0
7.0 10.4 21.9 3.5 5.2 11.0
the 21st century (e.g., documented in the In Vitro Diagnostic
(IVD) directive 98/79/EC), international umbrella organizations
such as the Joint Committee on Traceability in Laboratory Medicine
(JCTLM) (http://www.bipm.org/jctlm/), as well as national
metrology and reference institutes (www.bipm.org), and the
IVD-industry. In addition, (inter)national professional orga-
nizations, such as the International Federation of Clinical
Chemistry (IFCC) and the American Association of Clinical
Chemistry (AACC), have adoptedmetrological traceability, e.g.,
with the establishment of the IFCCCommission on Traceability in
LaboratoryMedicine (IFCCC-TLM) and theAACCHarmonization
Initiative (www.harmonization.net).
In West-European academic clinical laboratories, about
600 analytes are measured routinely [39]. These analytes can
be divided into ﬁve categories, depending on the complete-
ness of the traceability chain. Only analytes in category one
are traceable to SI units (Table 2) and can be standardized.
Standardization is achievedwhendifferentmeasurement pro-
cedures for one analyte provide the same test results. The
availability of JCTLM-listed reference materials (RMs) and/or
referencemeasurement procedures (RMPs) is, therefore, a pre-
requisite [40].
Reference materials are deﬁned as “materials sufﬁciently
homogeneous and stable with respect to one or more speci-
ﬁed properties, which have been established to be ﬁt for their
intended use in a measurement process” [7]. RMs that are
characterized by a metrologically valid procedure for one or
more of these properties, and are accompanied by a certiﬁcate
that provides the value of the speciﬁed property, its associated
uncertainty, and a statement of metrological traceability, are
called certiﬁed RMs (CRMs). In case a primary RM and/or a pri-
mary RMP is not available, itmay be possible to harmonize test
results; harmonization requires traceability of test results to a
speciﬁed RM, as well as a consensus agreement on the mea-
surement results (e.g., the average result of all tests). Despite
the large number of biomarkers routinely measured in clinical
chemistry laboratories, only approximately 10% of the assays
are currently standardized. Newly developed protein assays
are generally found in category ﬁve (Table 2).
Accredited reference measurement laboratories (AMRL)
will be required to anchor test results of qCCP methods to the
metrological traceability chain (Fig. 3), and the introduction
and general use of value-assigned human calibrators that
are traceable to a certiﬁed RM should enhance standard-
ization in this new area. The uncertainty introduced by the
value-assignment depends on the location in the traceabil-
ity chain [7,41]. For example, synthesis of (stable-isotope
translat ional proteomics 2 ( 2 0 1 4 ) 1–13 5
Table 2 – Traceability status in medical laboratory diagnostics: categories 1 and 2 analytes are generally standardized;
categories 3, 4 and 5 are often neither standardized nor harmonized.
Category Reference measurement
procedure
Primary (pure substance)
reference material
Secondary (value assigned)
reference material
Examples
1 Yes Yes Possible Electrolytes, glucose, cortisol
2 Yes No Possible Enzymes
3 Yes No No Haemostatic factors
4 No No Yes Protein tumour markers, HIV
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Abbreviations: HIV, human immunodeﬁciency virus; EBV, Epstein–Bar
abelled) peptide reference standards for quantitation of
rotein biomarkers in a bottom-up LC–MRM-MS approach
s straight-forward, whereas the availability of high quality
ntact-protein standards is limited. Nevertheless, it should
e noted that the exact determination of peptide content
“dry weight” and purity of synthetic peptides) introduces an
dditional step of uncertainty in the metrological traceability
hain. Moreover, metrological traceability of protein test
esults by the use of peptide calibrators is only possible if
omplete (stoichiometric) digestion is achieved, and so-called
imit peptides [42] can be used as surrogates for the protein
uantity. In this context, alternative internal and/or external
tandards should be considered that mimic the property of
he target protein during the entire (pre-) analytical workﬂow.
.3. Commutability of reference materials
ommutability is deﬁned as “the equivalence of the math-
matical relationship between the results of different
easurement procedures for RMs and for representative sam-
les from healthy and diseased individuals” [7]. In case an RM
s not-commutable and demonstrates behaviour that differs
rom that of native patient material, variable test results will
e obtained for patient sampleswith identical analyte concen-
rations when using the RM as a calibrator. This means that a
on-commutable calibration material breaks the traceability
hain.
Sample processing of RM can result in modiﬁcations of the
easurand and might be responsible for non-commutability
7]. For example, preparation of RM for lipids and apolipopro-
eins according to a strict protocol (CLSI C37-A) has shown
uch better commutability than commercially available
atient serum pools or RM prepared by regular procedures
7,43]. For several analytes, which are currently tested by
mmunoassays, standardization efforts proved unfeasible,
ecause of the lack of commutable RM (e.g., the tests of cardiac
roponin I, B-type natriuretic peptide and prostate-speciﬁc
ntigen) [44]. In such a complicated system of (two-step)
mmunoassays, molecular heterogeneity and minor changes
n the molecular structure or conformation of the RM can
nﬂuence the test result and cause non-commutability.
For standardization of qCCP methods, commutable, value-
ssigned secondary RMs, traceable to primary RMs, should
e developed in order to produce test results traceable to
tandards of higher order. As mentioned above, the use of pep-
ide reference standards necessitates, per deﬁnition, complete
roteolysis to guarantee full metrological traceability of the
rotein measurand. In addition, SIS-peptides are commonlyNo Proteins, EBV, VZV
s; VZV, Varicella-Zoster virus.
added after the digestionprocess anddonot correct for peptide
instability during proteolysis. Therefore, protein quantitation
based on peptide reference standards should include the addi-
tion of SIS-peptides prior to digestion to reduce variations in
peptide response. Alternatively, the use of more sophisticated
SIS-strategies, such as winged peptides [45,46], quantiﬁcation
concatemers [47], concatenated winged peptides [48], or full-
length proteins [49,50] can be considered.
An additional problem with the use of synthetic reference
peptides or proteins is the absence of analyte-free matrix
for preparation of calibration curves. In respect to all above-
mentioned concerns about the commutability of synthetic
peptide or protein reference standards, matrix-based, native,
and value-assigned, protein calibrators will provide most reli-
able absolute quantitation of endogenous proteins [51,52].
Because the protein standards are subjected to a work-up
that is identical to that of the unknown samples, they are
likely to correct for any variability in the (pre-) analytical work-
ﬂow. The use of a (single-point) matrix-based human plasma
external calibrator has, for example, shown to be effective for
the quantitation of apolipoproteins [51]. Obviously, absence of
matrix-effects has to be assured before native protein calibra-
tors can be used as (commutable) reference materials.
3. Pre-analytical quality requirements for
qCCP
In the current laboratory diagnostics, 70% of diagnostic mis-
takes are the result of pre-analytical errors [53]. To this end,
standardization of specimen collection and sample prepa-
ration in qCCP workﬂows (Fig. 1, left and middle part) is
pivotal. The quality guidelines as posed by the International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) can
function as a framework for drafting quality requirements for
qCCP workﬂows (www.ich.org). Such requirements will be dis-
cussed throughout in Sections 3 and 4. Note that this overview
leaves room for discussion whether the quality requirements
for pre-analysis and analytical test performance either have
to be met or should be interpreted as a consideration or spec-
iﬁcation.
3.1. Specimen collection and sample handlingThe (qCCP) process starts with specimen collection, e.g.,
blood, urine, saliva or cerebrospinal ﬂuid (CSF), from patients
who visit the hospital (Fig. 1). In this respect, the hospital
teo6 translat ional pro
infrastructure and the specimen collection facilities should
be “state-of-the-art” with positive sample identiﬁcation,
standardized protocols and employment of a track-and-trace
system for all materials from specimen collection until
storage [54,55]. Whereas specimen is deﬁned as a sample, as
of serum or plasma, urine, or CSF or another body ﬂuid, used
for analysis and diagnosis, we will here focus particularly on
the use of blood-derived samples for qCCP applications.
Blood collection can vary in numerous ways, and the inﬂu-
ence of various procedures on the peptide and protein content
has been the topic of several studies [56–58]. Serum has histor-
ically been used to archive patient materials [57], and remains
the most important matrix for clinical chemistry measure-
ments [59–61]. However, the ex vivo clotting of serum might
lead to neo-generation of peptides that might change the pep-
tide composition in the specimen [57,62]. For preparation of
plasma samples, on the other hand, several anticoagulants
can be used, and, depending on centrifugation conditions, a
certain degree of platelet depletion can be established [63]. As
shown in studies of the human proteome organization (HUPO)
plasma proteome project (PPP), there is a substantial con-
tribution of platelet-derived peptides to the total number of
peptides (in HUPO specimens) that might be explained either
by remaining platelets in the samples or by their activation
before removal [57,58].
According to HUPO PPP, no standard sample-processing
protocol could be deﬁned, due to the high number of sample
variables and the broad spectrum of analytical techniques
used. In a more recent study, the inﬂuence of several blood
collection tubes for MRM-MS-based measurement of tryptic
peptides from 55 plasma proteins was evaluated [63]. Even
for the mid- to high abundant plasma proteins, protein
release from platelets was suggested during the (delayed)
processing time of the samples. The authors follow the
recommendations for sample preparation as formulated
by HUPO PPP as well as the Members of the Early Detec-
tion Research Network (EDRN) [64] (http://ednr.nci.nih.gov/
resources/standard-operating-procedures/biological-specim-
ens). Although the EDRN protocol advised to refrigerate serum
or plasma samples until centrifugation, this study showed
that cold temperatures should be avoided to prevent platelet
activation [63].
Thus, better standardization of specimen collection and
sample handling requires international standard operating
procedures (SOPs). The SOPs for serum and plasma collection
can be based on the EDRN protocol, whereas the documenta-
tion on sample handling according to HUPO PPP can be used
as a guideline for sample work-up. For speciﬁc studies plasma
BD Vacutainer CTAD tubes containing citrate, theophylline,
adenosine and dipyrimadole (BD, NJ, US; Cat Nr 367947) are
recommended to suppress platelet activation [57,63–65]. In
case of serum samples, the so-called rapid serum tubes (BD
Vacutainer RST, Cat Nr 368771), which can provide a clotted
specimen within 5min after blood collection, can be useful
for qCCP purposes in order to reduce the pre-analytical error
[66]. To prevent degradation of labile proteins, blood collection
in the presence of protease inhibitors should be considered by
the use of e.g., BD P100 tubes (Cat Nr 366456) [63,67,68].
In addition to the conditions of specimen collection and
sample handling, pre-analytical variables such as patientmics 2 ( 2 0 1 4 ) 1–13
preparation (fasting or non-fasting), puncture site, and medi-
cation should be carefully documented [57]. Moreover, serum
indices that mark the degree of haemolysis, icterus and
lipaemia (HIL) of qCCP samples should be surveyed and doc-
umented as part of the sample-integrity check during sample
collection as an aid to annotate potentially affected results
[69]. Quality control of the pre-analytical phase should include
documentation of a set of quality indicators throughout the
process between the clinicians request and the start of the
analytical examination procedure [53].
3.2. Specimen storage and sample stability
To guarantee the (long-term) storage of specimens for qCCP,
stability of the protein biomarker(s) should be carefully
assessed. Stability assessment should, therefore, include the
various in-process conditions of the target protein as well as
the peptide analytes.
Uninterrupted and controlled storage of specimens below
−80 ◦C is normally recommended [64]. Stability tests for the
target protein can be performed by long-term, intermediate
and accelerated testing at storage conditions of −80 ◦C, −20 ◦C
and 4 ◦C, respectively. These tests are comparable to stability
tests of drug substances with storage conditions at ambient
temperatures (www.ich.org). Long-term stability tests should
normally be performed every three months over the ﬁrst year
and every six months over the second year (www.ich.org). In
addition, effects of freeze–thaw cycles require careful con-
sideration. To minimize the effect of multiple freeze–thaw
cycles, it is recommended to aliquot serum or plasma sam-
ples in volumes intended for single use only. Alternatively, or
complementary, addition of sample integrity markers at the
beginning of the qCCP workﬂow, i.e. at the time of blood col-
lection, can trace alterations in protease activity, which might
affect the stability of the target protein [70].
3.3. Sample work-up
Although digestion-free protein measurements are receiv-
ing growing attention in protein discovery and proteomics
studies (so-called top-down proteomics) [71], we will here
focus on the quantitative measurement of signature pep-
tides after (trypsin) digestion of high-abundance proteinswith
the use of LC–SID-MRM-MS. In case of high-abundance pro-
teins (mg/L–g/L range), crude serum samples can be used for
direct digestion [72,73]without prior sample puriﬁcation at the
protein level. For lower-abundance proteins, protein precipi-
tation, solid phase extraction, or immunoafﬁnity enrichment
may be suitable approaches to reduce sample complexity,
although at the risk to create additional bias and imprecision
[28,72,74–77].
Trypsin digestion can be considered as a “transforma-
tion” of the protein measurand into peptide analytes that
represent only minor part(s) of the protein molecule. There-
fore, digestion adds substantial complexity to the entire qCCP
workﬂow (Fig. 1, middle part). As an example, a thorough
inter-laboratory comparison demonstrated that imprecision
of peptide quantitation increased to 20–60% when trypsin
digestion of the target proteins was performed for individual
samples in eachparticipating laboratory [78,79]. Therefore, the
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nzymatic digestion requires critical evaluation. Documen-
ation and standardization of the source, type, and amount
f trypsin will be essential since these critical factors have
ll demonstrated to drastically affect trypsin digestion efﬁ-
iency [80,81]. The use of sequencing-grade modiﬁed trypsin
hat is resistant to autoproteolysis [82] is recommended, and
he ratio of trypsin-to-protein should be in the range of
:20–1:100 (w/w). The digestion efﬁciency can furthermore be
trongly inﬂuenced by chaotropic agents, surfactants and sol-
ents used during the denaturation, reduction, alkylation and
rypsin incubation steps [83]. Nevertheless, trypsin digestion
ime is the major determinant of the specimen turn-around
ime (deﬁned as the time fromsample receipt at the laboratory
orkstation to report in the hospital information system) and
ay be considered as one of the limitations of qCCP methods
hat will need further improvement.
The choice of signature peptide selection is another crucial
tep during method development for absolute quantitation
f biomarker proteins. Peptides generated during proteoly-
is may vary substantially in their rate of formation [83].
oreover, several peptides from the same protein showed
oor correlation in MS responses among patient samples [51].
ince the peptides derived from one protein may not all give
esults equivalent to the molar concentration of the protein
51,84,75], a minimal number of four to ﬁve peptides should
e selected during method development [73]. For develop-
ent of robust quantitative assays, peptides that are rapidly
ormed are preferred as these allow short incubation times
nd avoid variations due to missed cleavages and/or peptide
nstability [85,86]. Such rapidly formed peptides, which are
elected with regard to their cleavage efﬁciency, were recently
amed quantotypic, and are particularly attractive for selec-
ion in qCCP workﬂows [87]. In this respect, it is important to
ote that peptide selections inMS-based (targeted) proteomics
trategies for biomarker discovery and validation studies are
ommonly based on peptide unicity and detectability. Such
eptides, which are selected with regard to their high pro-
ein identiﬁcation or probability scores, are generally referred
o as proteotypic peptides, but do not take into account the
obustness of the trypsin digestion process.
In conclusion, standardization of the sample work-up for
CCP will require very careful adherence to SOPs in order to
chieve pre-deﬁned analytical performance goals (Fig. 1). In
ase of manual digestion protocols and large sets of sam-
les, wider variations in the test results are anticipated. The
se of automated (liquid handling) systems will be useful to
mprove overall analytical performance and throughput (i.e.
linical applicability) of qCCP methods [88]. Since turnaround
ime is strongly dependent on digestion future developments
n digestion-free top down quantitative proteomics are antic-
pated.
. Quality requirements for LC–MS/MS
uantitation.1. Analytical method performance
n-house developed qCCP methods should be thoroughly
valuated during method development and validation, andi c s 2 ( 2 0 1 4 ) 1–13 7
should follow the available guidelines for test evaluation
(www.ich.org) [5,89–91]. It should be noted that method devel-
opment and validation of qCCPworkﬂows additionally require
speciﬁc consideration of the peptide selection and digestion
(i.e. peptide recovery) process. Guidelines to address these par-
ticular issues are, however, not yet established. Because this
paper focuses on the speciﬁc requirements for implementa-
tion of qCCP, we will discuss on-going assurance of quality
requirements for analytical test performance during routine
use rather than the required validation parameters during test
development and validation.
4.1.1. Internal quality control
System reliability and LC–MS/MS performance are important
parameters tomonitor the accuracy of LC–MS/MSquantitation
of protein biomarkers (Fig. 1, right-hand side). During routine
analysis of patient specimens, internal quality control (IQC)
materials and control procedures are mandatory to provide
high error-detection and low false-rejection rates [92]. In clin-
ical chemistry, IQC materials are generally human, processed,
non-commutable materials with long-term shelf stability. IQC
ranges are commonly calculated by the use of a ‘state-of-the-
art performance’ approach, with appropriate CLSI protocols,
such as the CLSI Extended Protocol (EP)5, which includes the
estimation of within-run and total precision over a minimum
of 20 operating days [32,34].
In routine clinical chemistry laboratories, IQC data are
generally gathered and stored in the Laboratory Infor-
mation System (LIS) or in speciﬁc middleware during
system operation. The LIS or middleware automatically
detects system instability and inaccuracy when the IQC
samples exceed selected control rules. Typically, IQC is
performed at two levels, i.e. a physiological and patho-
physiological concentration. Frequently applied rules in
clinical chemistry labs are the Westgard rules (http://www.
westgard.com/westgard-rules-and-multirules.htm) [92]. IQC
samples may be included in all sample batches, but rational
use of IQC based on what is needed to have a “Six Sigma”
process is the future trend [93].
4.1.2. External quality assessment
Accreditation bodies demand that medical laboratories par-
ticipate in external quality assessment (EQA) surveys or pro-
ﬁciency testing (PT) programmes. EQA- or PT-providers inde-
pendently investigate and score comparability of test results of
individual labs to, e.g., gold standards (when target values are
available) or to peer group means (when target values are not
available). So far, only a limited number of EQA-organizations,
particularly category one EQA-organizations, have adopted
the metrological traceability concept and have assigned val-
ues to their EQA-materials with JCTLM-listed RMPs [94].
To enable value assignment, proven commutability of the
EQA-materials is a prerequisite. In case of value-assigned,
commutable EQA-materials, investigation of the standard-
ization or harmonization status of speciﬁc analytes among
different measurement procedures is feasible [94]. The Dutch
EQA-program is an example of a category one EQA-scheme in
which commutable sera for general clinical chemistry param-
eters are used. Equivalence of test results from general clinical
chemistry parameters has been investigated between 2005
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and 2010, i.e. far beyond the obliged implementation date of
the IVD Directive 98/79/EC. The evaluation revealed that stan-
dardization efforts can be monitored effectively when using
commutable, value-assigned EQA-materials [95].
With upcoming qCCP methods for clinical use, EQA- or PT-
providers should extend their EQA-schemes in such a way
that all critical steps of the qCCP workﬂow can be moni-
tored and compared among laboratories and qCCP method
users. Because qCCP method development should result in
medical tests that outperform contemporary immunoassays,
qCCP method groups should be deﬁned to enable analytical
head-to-head comparisons of immunoassays and SID-MRM-
MS methods.
In the proteomics community several proof-of-principle
EQA-programs have been organized so far which showed
results with interlaboratory CVs below 10% for most of the
signature peptides in multiplex MRM measurements when
digested samples were centrally prepared and distributed
[78,96]. However, interlaboratory CVs increased up to 20–60%
when the digestion was performed independently in all par-
ticipating laboratories [78]. More interlaboratory comparisons
are needed to investigate and improve test performance of
qCCP methods.
4.2. Chromatographic performance
A system suitability check should be performed regularly to
ensure proper functioning of the LC-system. Key parame-
ters for chromatographic behaviour include retention time
and peak-shape characteristics [23,27]. Because retention
time variability can be an indication of column degrada-
tion, or alterations in temperature or eluent composition,
observations of minor drifts allow rapid troubleshooting of
the LC–MS/MS system. In addition, monitoring of retention
time stability is particularly critical for robust quantitation
in multiplex LC–MS/MS methods that apply scheduling of
MRM transitions in different retention time windows. This
scheduling has the advantage that the MRM transitions are
not continuously measured during the complete chromato-
graphic run. However, small drifts in retention timemay cause
inadequate peak integration if the peak falls (partly) outside
the deﬁned window.
Peak shape characteristics, such as the full-width at half-
maximum (FWHM), or peak symmetry, allow the comparison
of chromatographic behaviour of peptides for one instrument
over time, and for different instruments at multiple sites [30].
An inter-laboratory evaluation of LC–SID-MRM-MS, for exam-
ple, revealed that measurement imprecision was severely
affected by inconsistent peak integration due to peak shape
abnormalities caused by LC-related problems [78].
Recommendations for the implementation of a system
suitability protocol for quantitative assessment of nano-
LC–MRM-MS performance have recently been proposed [30]
and include limits for (1) drifts and variation in retention time
and (2) variations in peak width and peak area. This study
demonstrated that visualization of decreased performance
that is often unnoticed could help to understand and mini-
mize variables that affect the quality of the measurement.
Routine control and monitoring of system pressure and
column temperature before, during and after analysis ismics 2 ( 2 0 1 4 ) 1–13
recommended to minimize changes in retention time, and
to allow reproducible peptide separation [97]. Batches and
suppliers of LC columns, reagents and standards should be
well-documented. Reagents and standards should be freshly
prepared and new columns should be installed on a regular
basis, depending on the nature and complexity of the injected
samples [23].
4.3. Mass spectrometric performance
The quality of MS performance can be mainly deﬁned by the
sensitivity of the mass detector, the speciﬁcity of the mass
analyzer, and the reproducibility of ionization and fragmenta-
tion in the ion source or collision cell, respectively.
4.3.1. Sensitivity
Monitoring of absolute MS signal intensities or, more speciﬁ-
cally, signal-to-noise (S/N) ratios of calibrators and/or internal
standards can serve as a measure for the MS detector sensitiv-
ity and, hence, the assay’s lower limit of quantitation (LLOQ),
limit of detection (LOD) and/orminimal detectable level (MDL).
The determination of S/N ratio, LOD/LLOQ and MDL can be
part of a system suitability check [30,98], preferably performed
with a system suitability sample that is similar to the target
analyte(s). Furthermore, regular tuning of the MS settings is
recommended to maintain sensitive MS detection.
In addition to peak intensity, variations in peak areas can
indicate potential degradation or adsorption of the peptide
analyte(s) during storage in the autosampler, and/or dur-
ing sample aspiration [30]. Suppression (or enhancement) of
ionization efﬁciency in the ESI source results in signal insta-
bility. This effect may be directly visible from decreased (or
increased) signal of the SIS-peptide, and can seriously affect
the reproducibility of MS detection [99,100]. For example,
phospholipids are well-known interferents and their presence
and inﬂuence on the assay can be further substantiated by
MRM analysis [23,101,102]. Monitoring of phospholipid and
platelet content might, therefore, be part of development and
validation of a quantitative proteomic method.
4.3.2. Speciﬁcity
Clinical immunoassays often suffer from non-speciﬁcity
which may be attributed to interference by autoantibodies
and/or anti-reagent antibodies. [1,2,52]. On the other hand,MS
is widely accepted for its high speciﬁcity and has the major
advantage that it allows direct detection of signature pep-
tides that can be identiﬁed with almost absolute certainty.
MS based qCCP methods might, therefore, overcome common
ﬂaws of immunoassays, especially since the protein analyte
is digested. However, also in MS analysis background signals
remain present and can interfere with the MRM-signal of the
target peptide, especially for quantitation in complexmixtures
such as serum or plasma [103,104].
In LC–MRM-MS on triple quadrupole instruments, one m/z-
value is selected for the precursor ion, whereas multiple m/z-
values can be selected to represent the speciﬁc product ions
formed after collision-induced dissociation (CID). At least one
product ion is selected for quantitation (quantiﬁer) and one for
conﬁrmation (qualiﬁer), and deviations in the ratio between
translat ional proteom
Table 3 – Maximum tolerance for relative ion intensities
using LC–MS/MS [27].
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traceability concept, adequate calibration with commutable>20–50% ±25
>10–20% ±30
≤10% ±50
uantiﬁer- and qualiﬁer-transition intensities can serve as an
ndication of interference by other compounds [105].
Some basic rules for this transition ratio in quantitative
RM-MS analysis are presented in Table 3. However, the
ctual tolerance for the ion-ratio settings of a speciﬁc target
eptide might also be determined by a “state-of-the-art per-
ormance approach” that is often used for clinical chemistry
pplications. This approach comprises the use of the average
ransition-ratio and SD, determined over a speciﬁed period of
ime (see Section 4.1.1). This may imply that tolerance limits
or the transition ratio are set tighter than presented in Table 3
n order to meet clinical chemistry performance goals.
Agreement of the transition ratiowith second, third ormul-
iple product ions will strengthen the deﬁnite identiﬁcation of
he signature peptide [29]. Nevertheless, the maximal num-
er of transitions should be balanced with the sensitivity of
he measurement of the quantiﬁer peptide ion (because an
ncreased number of MRM transitions reduces the average
well times). Therefore, acquisition of a limited number of
ata-points for additional transitions by so-called “triggered”
r “intelligent” MRM can offer quality control of multiple tran-
itions, while the reduction in MS dwell times is minimized. In
ddition, identiﬁcation of transitions with interferences in the
RM-MS data of samples by automatic comparison of peak
rea ratios (PARs) for multiple transitions of (1) the analyte
nd (2) the SIS-peptide has been described [29,106].
Monitoring the internal standard transitions should con-
rm whether deviations in transition ratio of the unlabelled
eptide are also observed for the SIS-peptide. Potential
nterference can furthermore be visualized by monitoring ion-
ransitions at different fragmentation conditions. Although
uch interfering peptides might produce identical, or very
imilar, parent-to-product transition ratios, it is unlikely that
hese peptides will also show the same ratio of intensities
or the transitions at different collision energies [105]. The
peciﬁcity ofMS detectionwith triple quadrupole instruments
an be further improved by enhancement of the resolution
f the mass analysers. Alternatively, the use of MS3 on, for
nstance, ion trap or hybrid triple quadrupole linear ion trap
nstruments provides an increased speciﬁcity in (peptide) MS
uantitation but may have a negative impact on sensitivity
22,107].
. Post-analytical quality requirements
.1. Reference intervals and decision limitsor unequivocal clinical application and interpretation, test
esults should be reported with reference intervals and/or
ecision limits. Reference ranges and/or decision limits willi c s 2 ( 2 0 1 4 ) 1–13 9
have to be determined according to existing guidelines, such
as the CLSI C28-A3 [108].
In case of standardized analytes, reference intervals and
decision limits need to be traceable to a standard of higher
order. The importance of traceable reference intervals and
decision limits is well-recognized by laboratory profession-
als and (inter)national clinical chemistry organizations, but
far less by the IVD-industry and the medical community.
Among the professional organizations the IFCC has estab-
lished a Commission on Reference Intervals and Decision
Limits (IFCC C-RIDL; www.ifcc.org) which, according to its
terms of reference, focuses on the traceability and univer-
sal application of reference intervals and decisions limits.
Successful international standardization programs like the
ones for serum creatinine, prostate-speciﬁc antigen and gly-
cated haemoglobin have the potential to improve clinical
decision-making around the globe [109]. In case of non-
standardized and non-harmonized analytes, method- and
manufacturer-speciﬁc reference intervals and/or decision lim-
its are applicable. This is currently the situation for type 4 and
5 protein analytes that are determined with immunoassays.
In addition, reference ranges and/or decision limits vary in
time and space when immunoreagents evolve to subsequent
generations and/orwhen immunoanalyzers are replaced. This
situation is very unfavourable and ineffective, leading to
confusion among clinicians, hampering patient safety and
preventing universal and even national or regional use of clin-
ical guidelines.
Successful implementation of the traceability concept for
qCCPmethodswith the use ofMS, alongwith unequivocal def-
initionsof the “measurand”, should enable thedevelopment of
traceable reference intervals and/or decision limits. It should
be kept in mind that due to the high speciﬁcity of MS, the
measurand in MS-based qCCP methods may be different from
the entitiesmeasured in clinical immunoassays, which neces-
sitates the determination of new reference ranges and/or
decision limits. With an increasing number of labs involved in
qCCP, EQA- and professional clinical chemistry organizations
should collaborate from the start and initiate joint projects
to determine traceable reference intervals and/or decision
limits for protein measurands quantitated with qCCP-based
MS-assays.
6. Conclusions
To safeguard analytical performance of qCCPmethods, careful
attention to the pre-analytical phase is needed for speci-
men collection, transport, storage and stability. In particular
for protein biomarker panels, guidelines should furthermore
be established that address the speciﬁc issues related to
qCCP applications, e.g., the selection of robust and quanto-
typic peptides as surrogates for the single protein biomarker.
These special qCCP guidelines should also consider the pre-
analytical steps of sample preparation and protein digestion.
The LC–MS/MS analysis should include implementation of thestandards, normalization with stable isotopically labelled
standards, and proper use of internal quality control (IQC)
samples and rules, as well as control of chromatographic
teo
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and MS performance. Analytical quality speciﬁcations for
qCCP methods should be rationalized and pre-deﬁned, e.g.,
according to the StockholmConferenceHierarchy [35]. In addi-
tion, post-analytical quality requirements for qCCP methods
should particularly include traceable reference intervals and
clinical decision limits, if feasible. Furthermore, external qual-
ity assessment (EQA) scheme-organizers should adapt their
EQA-schemes to enable testing of all major critical steps in
MS-based quantitative proteomics. In addition, EQA-providers
should evaluate protein standardization and harmonization
efforts by means of commutable EQA-materials for all types
of body ﬂuids.
7. Future perspectives
From the large number of protein biomarkers that have so
far been discovered there are only a few that successfully
make it into laboratory medicine [110]. The enormous gap
between scientiﬁc discovery and clinical applicability can be
explained, on the one hand, by tedious FDA- and CE (Con-
formité Européenne)-procedures in combination with huge
costs for IVD-manufacturers to manufacture immunoassays,
and, on the other hand, by the limited success for the devel-
opment of new biomarkers to the level of routine medical
tests. In this era of rapidly evolving technology and scientiﬁc
insights, this situation seriously hampers implementation of
good candidate biomarkers and potential medical tests in the
ﬁeld of laboratory medicine. One might hope that disruptive
technologies should help IVD-industry and laboratory profes-
sionals to bridge this gap.
The authors believe that the disconnect between pro-
tein biomarker discovery and routine test application can,
to a certain extent, be solved by robust, multiplexed,
and standardized alternative technologies. In our opinion,
MS-based qCCP has the potential to replace or at least sup-
plement quantitative clinical immunoassays provided the
MS-based methods are robust, immunoassay-independent,
cost-effective, and standardizable. Moreover, when clini-
cally acceptable turnaround times can be realized the
MS-basedqCCPassays canbepowerful alternatives for current
immunoassays, especially because they will offer opportu-
nities for multiplexed evaluation of candidate biomarker
panels. Standardization of the qCCP methods implies that the
concepts ofmetrological traceability andcommutability of cal-
ibrators can be applied successfully. In that case it is feasible to
standardize test results to a gold standard RM and RMP, and/or
to harmonize to a pre-deﬁned RM.
Standardization of qCCP based protein assays provides
traceable reference intervals and decision limits, which will
support patient safety and unequivocal interpretation of test
results. It is realistic to note that MS can only become
an enabling technology for protein quantitation when joint
efforts for complete test evaluations are made by all involved
stakeholders.
Overall, analytical performance of qCCP assays should
meet pre-deﬁned analytical performance criteria for impreci-
sion, bias and allowable total error, to be clinically useful. This
allows consistent implementation of the traceability concept
and enabling global standardization of test results, referencemics 2 ( 2 0 1 4 ) 1–13
intervals and decision limits. Therefore, automation of the
pre-analytical, analytical and post-analytical steps in MS-
basedproteomicsworkﬂows is necessary in order to guarantee
robust applications and future CE-marking or FDA-approval.
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